ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
125.791,50
-1,27%
S&P 500
5.294,15
-0,51%
US Dollar vs BRL
5,1562
0,64%
Bitcoin
69.630,54
-0,71%
Brent Oil
81,54
-1,10%
Registration Strip Icon for smarter Negocie de forma mais inteligente, não mais difícil: Libere seu potencial com nosso conjunto de ferramentas e discussões ao vivo.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Kintara Therapeutics Inc (KTRA)

  7. Kintara Therapeutics Inc (KTRA) Notícias

KTRA

Kintara Therapeutics (KTRA)

Kintara Therapeutics Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:KTRA
DataHoraFonteTítuloCódigoCompanhia
17/05/202417:10Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:KTRAKintara Therapeutics Inc
17/05/202417:05Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:KTRAKintara Therapeutics Inc
14/05/202417:55Edgar (US Regulatory)Form 425 - Prospectuses and communications, business combinationsNASDAQ:KTRAKintara Therapeutics Inc
14/05/202417:50Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KTRAKintara Therapeutics Inc
14/05/202417:45PR Newswire (US)Kintara Therapeutics Announces Fiscal 2024 Third Quarter Financial ResultsNASDAQ:KTRAKintara Therapeutics Inc
14/05/202417:40Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:KTRAKintara Therapeutics Inc
13/05/202417:06Edgar (US Regulatory)Form S-4 - Registration of securities, business combinationsNASDAQ:KTRAKintara Therapeutics Inc
05/04/202414:09PR Newswire (US)Kuehn Law Encourages KTRA, ABIO, SWAV, and NS Investors to Contact Law FirmNASDAQ:KTRAKintara Therapeutics Inc
03/04/202408:00PR Newswire (US)Kintara Therapeutics and TuHURA Biosciences Enter into Definitive Merger AgreementNASDAQ:KTRAKintara Therapeutics Inc
27/03/202410:00PR Newswire (US)Kintara Therapeutics Announces Expansion of REM-001 Clinical Study to Include Patients on PembrolizumabNASDAQ:KTRAKintara Therapeutics Inc
14/02/202418:07PR Newswire (US)Kintara Therapeutics Announces Fiscal 2024 Second Quarter Financial Results and Provides Corporate UpdateNASDAQ:KTRAKintara Therapeutics Inc
12/02/202411:00PR Newswire (US)Kintara Therapeutics Announces Initiation of REM-001 Clinical Trial for the Treatment of Cutaneous Metastatic Breast CancerNASDAQ:KTRAKintara Therapeutics Inc
18/12/202318:05Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:KTRAKintara Therapeutics Inc
07/12/202311:00PR Newswire (US)Kintara Therapeutics Announces Review of Strategic AlternativesNASDAQ:KTRAKintara Therapeutics Inc
05/12/202311:00PR Newswire (US)Kintara Therapeutics Granted Extension by Nasdaq to Regain Compliance with the Stockholders' Equity Continued Listing RequirementNASDAQ:KTRAKintara Therapeutics Inc
13/11/202318:10PR Newswire (US)Kintara Therapeutics Announces Fiscal 2024 First Quarter Financial Results and Provides Corporate UpdateNASDAQ:KTRAKintara Therapeutics Inc
31/10/202309:00PR Newswire (US)Kintara Therapeutics Announces Preliminary Topline Results From GBM AGILE StudyNASDAQ:KTRAKintara Therapeutics Inc
27/10/202317:05Edgar (US Regulatory)Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]NASDAQ:KTRAKintara Therapeutics Inc
04/10/202317:35Edgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:KTRAKintara Therapeutics Inc
21/09/202310:35GlobeNewswire Inc.Dawson James Securities Announces October Date for 8th Annual Small Cap Growth ConferenceNASDAQ:KTRAKintara Therapeutics Inc
18/09/202317:25Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:KTRAKintara Therapeutics Inc
01/09/202319:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KTRAKintara Therapeutics Inc
01/09/202317:05Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:KTRAKintara Therapeutics Inc
15/06/202316:32Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:KTRAKintara Therapeutics Inc
11/05/202309:02Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:KTRAKintara Therapeutics Inc
31/03/202317:17Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:KTRAKintara Therapeutics Inc
31/03/202317:15Edgar (US Regulatory)Annual Report to Security Holders (ars)NASDAQ:KTRAKintara Therapeutics Inc
13/02/202318:30Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:KTRAKintara Therapeutics Inc
30/12/202218:58ValueWalkIs Kintara Therapeutics A Hidden Gem?NASDAQ:KTRAKintara Therapeutics Inc
28/11/202214:42TipRanksKintara Therapeutics Shares (NASDAQ: KTRA) Surge after Receiving Fast Track DesignationNASDAQ:KTRAKintara Therapeutics Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:KTRA

Seu Histórico Recente

BIT
S29800
Societe Generale Effekten
NYSE
CUBI-D
Customers Bancorp
TSXV
SFL.P
ASX
ORGKOA
BOV
SUZBJ480
SUZBJ480 Ex:48
BIT
P12AN1
BNP PARIBAS ISSUANCE
ASX
VESNA
BIT
S30627
Societe Generale Effekten
UNSW
BULKETH
Bulk Token
EU
XS2451856269
ABN Amro Bank NV Aab1.07...
NASDAQ
FATPW
Fat Projects Acquisition
BIT
SSPX3S
Societe Generale Effekten
EU
H858S
H858S
COIN
SRNBTC
SIRIN LABS Token
BOV
UNHH34M
Unitedhealth
ASX
CAMBA
Delayed Upgrade Clock
ADVFN Logo

Brasil
Empresa
Negócios
Popular
Obter o aplicativo

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados